Effect of potassium bicarbonate supplementation on muscle protein synthesis in older wome
- Conditions
- SarcopeniaOsteoporosisMusculoskeletal - Other muscular and skeletal disordersMusculoskeletal - Osteoporosis
- Registration Number
- ACTRN12622001444774
- Lead Sponsor
- Dr Caoileann Murphy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 20
Women aged between 65 and 90 y
- 24-h urine pH of less than or equal to 6.7 at screening
•Self-reported history of conditions impacting acid-base balance (i.e. renal disease, addison’s disease, severe COPD with CO2 retention, kidney stones in last 2 years, liver cirrhosis), active hyperparathyroidism, untreated thyroid disease, significant immune disorders, unstable heart disease, primary aldosteronism, active malignancy, type 1 diabetes mellitus, active inflammatory bowel disease, neuromuscular disease (e.g. Myasthenia gravis, MS, muscular dystrophies, MND), Parkinson’s disease
•Medications that can impact acid-base balance, skeletal muscle / bone turnover (i.e. current use of diuretics, antacids containing aluminum hydroxide or magnesium hydroxide), HRT, insulin, drugs affecting bone turnover (bisphosphonates or denosumab in the last year, other osteoporosis medications [Tamoxifen/raloxifene, calcitonin, oestrogen] in the last 3 months, glucocorticoids for >10 days in the last 3 months), simvastatin / zocor, oestrogen suppressants , warfarin, anticoagulants other than aspirin (will be stopped 3 days prior to each biopsy)
•Glomerular filtration rate (GFR) <51 mL/min/1.73m2 and a serum potassium >5.3 mmol/L (assessed during participant screening)
•Regular resistance structured training (> 1 sessions of structured training / week)
•Participants taking nutritional supplements will be asked to cease taking these 2 weeks prior to, and for the duration of the study, including potassium-containing salt substitutes
•Total walking incapacity
•Women must be at least 1 year since last menses
•Smokers
•Bone mineral density (BMD) T-score below -2.5 at the lumbar spine or total hip
•Cachexia – defined as unintentional weight loss > 5% in last 6 months or, in persons with BMI < 20 kg/m2 weight loss > 2%, or low muscle mass (ASMI < 7 kg/m2 in men, < 5.5 kg/m2 in women) plus > 2% weight loss in individuals with an underlying condition associated with cachexia
•Current infectious disease or diagnosis of bloodborne disease
•Allergy to local anaesthesia
•Mini Mental State Examination (MMSE) score < 24
•If participant’s GP reports they have an excluded condition or are taking an excluded medication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method